

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gladwin et al.

Application No. 10/563,683

Filed: January 6, 2006

Confirmation No. 3225

For: USE OF NITRITE SALTS FOR THE
TREATMENT OF CARDIOVASCULAR
CONDITIONS

FILED VIA EFS

Examiner:

Art Unit: 1616

Attorney Reference No. 4239-67618-07

FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above is a **Response to Notification of Defective Response and Request for Correction of Inventorship (under 37 CFR 1.497)**, supported by the following:

- ☒ Copy of Notification of Defective Response dated November 9, 2006 (2 pages)
- ☒ Statement Under 37 C.F.R. 1.497(b) Regarding Inventorship (signed by Richard O. Cannon III) (1 page)
- ☒ Assent by Assignee Under 37 C.F.R. 1.497(b) to Addition of Inventor, from each Joint Assignee as follows:
 - The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (2 pages)
 - The University of Alabama Research Foundation (1 page)
 - Wake Forest University (1 page)
 - Loma Linda University (1 page)
 - The Board of Supervisors of Louisiana State University (1 page)
- ☒ Copy of Combined Declaration and Power of Attorney, originally submitted October 4, 2006 (24 pages)
- ☒ The Director is hereby authorized to charge the required processing fee under §1.17(i) (\$130.00) to Deposit Account No. 02-4550.

☒ The Director is hereby authorized to charge any additional fees that may be required for this filing, or credit over-payment, to Deposit Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630